ISOP_Logo_Final
+1-908-253-3608
info@go-isop.org
Facebook
Twitter
LinkedIn
YouTube
  • About ISoP
    • Constitution and By-laws
    • Five-Year Strategic Plan
    • Leadership Team
    • Awards
    • ISoP Fellows
    • Member Spotlight
    • Logo Usage Policies
    • Communications Guidelines
    • Memorial Policy
    • discuss.go-isop.org
    • Photo Gallery (Flickr)
    • Contact Us
  • Events
    • ACoP
    • PAGE
    • WCoP
    • AAPS
    • ACCP
    • ASCPT
    • PAGANZ
    • PAGJA
    • Pharmacometrics Network Benelux
    • PKUK
    • RedIF
    • SUP
  • Membership
    • Member Profile
    • Join
    • Renew
    • Volunteer
  • Training Material
    • Tutorials
    • ISoP YouTube Channel
    • Shiny Server
    • Resources
  • SIGs
    • Clinical Pharmacometrics
    • Mathematical and Computational Sciences (MCS)
    • Quantitative Systems Pharmacology (QSP)
    • Statistics and Pharmacometrics (SxP)
  • Committees
    • Awards Committee
    • Communications Committee
    • Conference Committee
    • Diversity Equity & Inclusion (DE&I) Committee
    • Education Committee
    • Executive Committee
    • Finance Committee
    • Membership Committee
    • Nominations Committee
    • Scientific Partnership Committee
    • Standards & Best Practices Committee
    • Technology Committee
  • Trainee Community
  • Local Groups
    • Midwest
    • New England
    • NJ/PA/NY
  • Official Journals
    • Recent Publications
    • Newsletters
  • Career Center
Loading Events

« All Events

Leveraging IPF QSP Modeling and Simulated Patients to Build a Model of SSc-ILD

March 22 @ 11:00 am - 12:00 pm

  • « Swing Into Summer Local Event
  • A Gentle Introduction to Optimal Design for Pharmacometric Models »

Systemic sclerosis (SSc) is a rare connective tissue and autoimmune disease associated with inflammation of the skin and internal organs. Interstitial lung disease (ILD), a frequent complication of SSc with highly variable patient course, is associated with increased risk of morbidity and mortality. Mechanistic, mathematical modeling approaches have been applied to a similar disease area, idiopathic pulmonary fibrosis (IPF), to support the development of new drug treatments by improving understanding of disease pathophysiology, identifying mechanistic drivers of disease, interpreting clinical treatment results, and assessing efficacy for novel treatments as monotherapies or in combination with existing treatments.

ILDsym, a quantitative systems pharmacology (QSP) model of SSc-ILD, was built by leveraging the design framework from IPFsym. New sub-models were developed and components updated where appropriate to represent SSc-ILD. Aspects of this development process and simulated patient generation will be discussed, along with how standard of care treatments have been represented in the model which set the stage for novel treatment assessment.

Click the image to register for the webinar!

+ Google Calendar+ iCal Export

Details

Date:
March 22
Time:
11:00 am - 12:00 pm
Event Category:
ISoP Events
Website:
https://us02web.zoom.us/webinar/register/WN_bor3UlNARtCMjPd2GcqujA

Venue

Virtual – Eastern Time Zone (EST)
NY

Organizer

ISoP MCS SIG
  • « Swing Into Summer Local Event
  • A Gentle Introduction to Optimal Design for Pharmacometric Models »
Copyright 2021 by ISoP
Privacy Statement

International Society of Pharmacometrics
1200 Rt 22E Suite 2000
Bridgewater, NJ 08807
United States

+1-908-253-3608
info@go-isop.org
@ISoP1